Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 27, 2017
Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
PALO ALTO, Calif., July 27, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced ...
July 27, 2017
Researchers to Present Clinical Data Supporting Use of Xoft System for Endometrial Cancer Treatment at American Association of Physicists in Medicine Annual Meeting & Exhibition
NASHUA, N.H. and DENVER, July 27, 2017 (GLOBE NEWSWIRE) -- (Booth #6010) -- iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and ...
July 27, 2017
Achaogen to Host Conference Call and Webcast of Second Quarter 2017 Financial Results on August 3, 2017
SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant ...
July 27, 2017
Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017
WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
July 26, 2017
VALNEVA and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus
Lyon (France), July 26, 2017 - Valneva SE (VLA), a fully integrated, commercial stage biotech company focused on developing innovative, life-saving vaccines, announces today that ...
July 26, 2017
Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration
OSAKA, Japan and SAN DIEGO, July 25, 2017 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co. Ltd. (Santen) and TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) (TRACON) today announced that ...
July 26, 2017
Kiadis Pharma proposes former Actelion COO Otto Schwarz as new Supervisory Board member
Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations ...
July 26, 2017
Foamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled for August 9
REHOVOT, Israel and BRIDGEWATER, N.J., July 26, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing ...
July 25, 2017
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
IRVING, Texas, July 25, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc.(Nasdaq: RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced its intention to offer and ...
July 25, 2017
BioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient Enrollment in the US
ALAMEDA, Calif.--(BUSINESS WIRE) -- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that the Data ...
July 25, 2017
Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus
Transgene (TNG.PA) (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, announces that new and encouraging preclinical data on its next generation ...
July 25, 2017
Soleno Therapeutics Announces Sale of Non-Strategic Assets to Flexicare, Inc.
REDWOOD CITY, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
July 25, 2017
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEWARK, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
July 25, 2017
BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel, July 25, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...
July 25, 2017
Gemphire Enters Into $15 Million Term Loan Agreement With Silicon Valley Bank
LIVONIA, Mich., July 25, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced that it has entered into a loan and security agreement with ...
July 25, 2017
Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections
SOUTH SAN FRANCISCO, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative ...
July 25, 2017
Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies”
NEWTOWN, Pa., July 25, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small ...
July 24, 2017
VALNEVA Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15
Lyon (France), July 24, 2017 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, ...
July 24, 2017
Reata’s Bardoxolone Methyl Demonstrated Improved Kidney Function in Patients With Alport Syndrome in Ongoing Phase 2 Portion of Phase 2/3 Cardinal Study
IRVING, Texas, July 24, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals Inc. (RETA) (“Reata” or “the Company”) today reported initial data from the ongoing open-label Phase ...
July 24, 2017
Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
PALO ALTO, Calif., July 24, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced completion of ...
Page 104 of 117